Statements (23)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:biotechnology
|
| gptkbp:acquiredBy |
gptkb:Bristol-Myers_Squibb
|
| gptkbp:acquisitionYear |
2012
|
| gptkbp:focusesOn |
diabetes treatment
metabolic disorders |
| gptkbp:foundedIn |
1987
|
| gptkbp:founder |
gptkb:Howard_E._Greene_Jr.
|
| gptkbp:headquartersLocation |
gptkb:San_Diego,_California,_United_States
|
| https://www.w3.org/2000/01/rdf-schema#label |
Amylin Pharmaceuticals
|
| gptkbp:industry |
gptkb:biotechnology
|
| gptkbp:keyPerson |
gptkb:Mark_G._Foletta
gptkb:Christian_Weyer gptkb:Daniel_M._Bradbury |
| gptkbp:notableProduct |
gptkb:Bydureon
gptkb:Byetta gptkb:Symlin |
| gptkbp:numberOfEmployees |
~500 (at time of acquisition)
|
| gptkbp:status |
defunct
|
| gptkbp:stockSymbol |
gptkb:AMLN
|
| gptkbp:tradedOn |
gptkb:NASDAQ
|
| gptkbp:website |
www.amylin.com
|
| gptkbp:bfsParent |
gptkb:Bristol_Myers_Squibb
|
| gptkbp:bfsLayer |
6
|